{
    "nct_id": "NCT05805501",
    "official_title": "A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* International Metastatic RCC Database Consortium (IMDC) risk intermediate (score of 1 or 2) or poor (score of 3-6)\n* Measurable disease with at least one measurable lesion\n* Histologically confirmed ccRCC with or without sarcomatoid features\n* Negative for HIV, hepatitis B, or hepatitis C virus (HCV)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 90 days after the final dose of tiragolumab, 4 months after the final dose of tobemstomig (RO7249669) and pembrolizumab, or for 1 week after the final dose of axitinib, whichever occurs last\n* Inability to swallow a tablet or malabsorption syndrome\n* Prior treatment for localized and/or metastatic RCC with systemic RCC-directed therapy, including T-cell costimulating or immune checkpoint blockade therapies\n* Ongoing use or anticipated need for treatment with a strong CYP3A4/5 inhibitor or inducer\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Uncontrolled or symptomatic hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\n* Moderate to severe hepatic impairment (Child-Pugh B or C)\n* Uncontrolled hypertension\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* Significant cardiovascular/cerebrovascular disease within 3 months (12 months for UK participants) prior to randomization\n* History of clinically significant ventricular dysrhythmias or risk factors for ventricular dysrhythmias\n* History of congenital QT syndrome\n* Resting heart rate (HR) > 100 bpm (or clinically significant tachycardia)\n* Stroke (including transient ischemic attack), myocardial infarction, or other symptomatic ischemic event, or thromboembolic event (e.g., deep venous thrombosis [DVT], pulmonary embolism [PE]) within 3 months (12 months for UK participants) before randomization\n* Significant vascular disease (e.g., aortic aneurysm or arterial dissection requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of Cycle 1\n* Tumors invading pulmonary blood vessels, cavitating pulmonary lesions or known endobronchial disease\n* Tumor invading the gastrointestinal (GI) tract, including abdominal or tracheoesophageal fistulas\n* Evidence of abdominal free air not explained by paracentesis or recent surgical procedure\n* Active peptic ulcer disease, acute pancreatitis, acute obstruction of the pancreatic or biliary duct, appendicitis, cholangitis, cholecystitis, diverticulitis, gastric outlet obstruction\n* Intra-abdominal abscess within 6 months before initiation of study treatment\n* Clinical signs or symptoms of GI obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding\n* Evidence of bleeding diathesis or significant coagulopathy\n* Grade â‰¥ 3 hemorrhage or bleeding event within 28 days prior to initiation of study treatment\n* Clinically significant hematuria, hematemesis, hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood, coagulopathy, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 3 months before initiation of study treatment\n* Active or history of autoimmune disease or immune deficiency\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* History of another primary malignancy other than RCC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%)\n* Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live, attenuated vaccine will be required during the study\n* Active tuberculosis (TB)\n* Severe infection within 4 weeks prior to initiation of study treatment\n* Participants with active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n* Known hypersensitivity to Chinese hamster *ovary cell products or to any component of tobemstomig, tiragolumab, pembrolizumab, or axitinib",
    "miscellaneous_criteria": ""
}